PolyNovoPNV 
-3.91%24h
PolyNovo (PNV) Stock Overview
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell Implant to host pancreatic islet cells in the skin; NovoSorb MTX for the treatment of varying complex wounds; and plastics and reconstructive device product. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
PNV Stock Information
PolyNovo (PNV) Price Chart
PolyNovo Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $1.66 | N/A |
| Market Cap | $1.14B | N/A |
| Shares Outstanding | 684.45M | 3.57% |
| Employees | 218.00 | N/A |
| Shareholder Equity | 65.38M | 269.08% |
Valuation | 2023 | Change |
|---|---|---|
| P/E Ratio | -231.15 | N/A |
| P/S Ratio | 25.81 | N/A |
| P/B Ratio | 17.42 | N/A |
Growth | 2023 | Change |
|---|---|---|
| Return on Equity | -0.0510 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $44.14M | N/A |
| Earnings | -$3.33M | N/A |
| EPS | -0.0072 | N/A |
| Earnings Yield | -0.0043 | N/A |
| Gross Margin | 0.932 | N/A |
| Operating Margin | -0.0948 | N/A |
| Net income margin | -0.0755 | N/A |
Financial Strength | 2023 | Change |
|---|---|---|
| Total Assets | $62.66M | N/A |
| Total Debt | $10.85M | N/A |
| Cash on Hand | $31.73M | N/A |
| Debt to Equity | 0.2818 | -57.23% |
| Cash to Debt | $2.92 | 422.38% |
| Current Ratio | $5.32 | 154.74% |
